Spektus Pharma Inc. (Spektus) and GEBRO Holding GmbH (GEBRO) announced a strategic global commercialization partnership for ActraFlex, a novel twice-daily extended-release formulation of tramadol/paracetamol for the management of pain.
ActraFlex combines Spektus’ patented AmyloFlex drug-delivery platform technology with GEBRO’s established Diliban tramadol/paracetamol product, creating a differentiated extended-release formulation designed to provide sustained drug release with convenienttwice-dailydosing.
Under the partnership, GEBRO will lead commercialization and supply across Europe and selected Rest of World (RoW) markets, anchored by Spain, where Diliban has an established regulatory and commercial foundation. Spektus will lead commercialization and supply across North America, South America and selected RoW markets, through its established network of regional commercialization partners.
The partnership brings together GEBRO’s established expertise and commercial presence in pain management with Spektus’ proprietary drug-delivery technology and global partnership network. Together, the companies intend to leverage their complementary capabilities and geographic reach to bring ActraFlex to patients across multiple international markets.
“Our partnership with GEBRO highlights the potential of Spektus’ proprietary AmyloFlex technology to create differentiated specialty medicines from established products and brands. Building on GEBRO’s successful commercialization of Diliban in Europe, we see strong commercial potential for ActraFlex across the Americas and selected markets in Africa and Asia.” said Zarvaan Merchant, CEO of Spektus Pharma.
“GEBRO brings deep expertise in pain management and a strong foundation with Diliban in Europe. Together with Spektus’ established commercialization partner network across the Americas and other international markets, we believe ActraFlex has the potential to become an important global product in pain management,” said Christian Kollenz, managing director of Gebro Holding
